Instrument Inactif

Communiqués DIUL GROUP

Actions

DNL

GB00BDB6Q760

Communiqués

14/09/22	Diurnal : Interim Results for the Twelve Months Ended 30 June 2022	PU
31/08/22	Form 8.3 - [Diurnal Group plc - 30 08 2022 - Opening Declaration] - (HHL)	AQ
31/08/22	SVM Asset Management - Form 8.3 - Diurnal Group plc	PR
26/07/22	Diurnal : Trading Update	PU
30/03/22	Diurnal : Distribution agreement signed with Vector Pharma for Alkindi®	PU
22/03/22	Diurnal : Interim Results for the Six Months Ended 31 December 2021	PU
11/01/22	Diurnal : Operational update - Jan 2022	PU
16/11/21	Diurnal : Alkindi® approved by Swissmedic for use in Switzerland	PU
15/11/21	Diurnal : Eton Pharmaceuticals enters into US co-promotion deal for Alkindi Sprinkle®	PU
15/11/21	Diurnal : Directorate Changes	PU
14/10/21	Diurnal : Distribution agreement signed with ExCEEd Orphan for Central and Eastern Europe	PU
11/10/21	Diurnal : Phase 1 data for DITEST™ published in European Journal of Endocrinology	PU
14/09/21	Diurnal : Full Year Results for the year ended 30 June 2021	PU
13/09/21	Diurnal : Commercial launch of Efmody® in the UK	PU
01/09/21	Diurnal : launches Efmody® in Germany and Austria	PU
28/07/21	Diurnal : Business and trading update - July 2021	PU
12/07/21	Diurnal : receives Special Protocol Assessment Agreement for Chronocort® from the FDA	PU
02/07/21	Diurnal : receives Marketing Authorisation for Efmody® in Great Britain from the MHRA	PU
29/06/21	Diurnal : Distribution agreement with Er-Kim for Bulgaria and Romania	PU
01/06/21	Diurnal : triggers $1.25m in milestone payments from Citrine Medicine	PU
23/02/21	Diurnal : Interim Results for the Six Months Ended 31 December 2020	PU
23/02/21	Diurnal : Chronocort® distribution and marketing agreement with Consilient Health for the Nordics	PU
02/02/21	Diurnal : Chronocort® Phase 3 and Safety Extension Study results published in JCEM	PU
27/01/21	Diurnal : China licencing agreement with Citrine Medicine for Alkindi®	PU
14/01/21	Diurnal : Business and trading update	PU